Simvastatin Preserves the Ischemic-Reperfused Myocardium in Normocholesterolemic Rat Hearts

Allan M. Lefer, PhD; Barry Campbell, BA; Yong-Kyoo Shin, MD; Rosario Scalia, MD, PhD; Reid Hayward, PhD; David J. Lefer, PhD

Background—Ischemia followed by reperfusion in the presence of polymorphonuclear leukocytes (PMNs) results in cardiac contractile dysfunction as well as cardiomyocyte injury. These deleterious effects are due in large part to endothelial dysfunction leading to the upregulation of cell adhesion molecules and subsequent neutrophil-endothelium interaction. At clinically relevant doses, simvastatin, an HMG-CoA reductase inhibitor, has been shown to lower serum cholesterol levels and normalize endothelial cell function. We wanted to test the effects of simvastatin on neutrophil-mediated cardiac dysfunction in a controlled model of myocardial ischemia-reperfusion.

Methods and Results—This study examines the effects of simvastatin in a neutrophil-dependent isolated perfused rat heart model of ischemia (I) (20 minutes) and reperfusion (R) (45 minutes) injury. Administration of simvastatin 25 μg/rat improved coronary flow and preserved left ventricular developed pressure (LVDP) and dP/dt max, indexes of cardiac contractile function. Final LVDP was 95 ± 5 mm Hg in I/R hearts perfused with PMNs and simvastatin, compared with 49 ± 4 mm Hg in PMN-perfused I/R hearts receiving only vehicle (P < 0.001). In addition, simvastatin significantly reduced PMN accumulation in the ischemic myocardium (P < 0.01). In PMN-perfused rat hearts after I/R, simvastatin also significantly attenuated P-selectin expression, CD18 upregulation in rat PMNs, and PMN adherence to rat vascular endothelium. Significant, although less potent, effects were obtained with pravastatin.

Conclusions—These results provide evidence that HMG-CoA reductase inhibitors are potent and effective cardioprotective agents that inhibit leukocyte-endothelial cell interactions and preserve cardiac contractile function and coronary perfusion after myocardial ischemia and reperfusion. Moreover, these effects are unrelated to the cholesterol-lowering action of this agent and appear to be mediated by enhanced endothelial release of NO. (Circulation. 1999;100:178-184.)

Key Words: simvastatin ■ ischemia ■ reperfusion ■ myocardium ■ leukocytes

Prompt and effective reperfusion of the ischemic myocardium plays an important role in minimizing cardiomyocyte injury associated with acute myocardial ischemia. However, myocardial reperfusion itself results in enhanced myocardial injury.1,2 The process of reperfusion injury is characterized by an inflammatory response in which polymorphonuclear leukocytes (PMNs) play an important role.2,3 On reperfusion, many activated PMNs accumulate in the coronary microvasculature and infiltrate into the myocardium.4,5 Activated PMNs can stimulate tissue injury by the release of a variety of cytotoxic substances, including oxygen-derived free radicals, inflammatory cytokines, and proteases.6 Many of these substances also mediate vascular endothelial dysfunction as well as myocardial cell injury.7 This process is also consistent with evidence that either decreasing the number of circulating PMNs or administration of monoclonal antibodies directed against neutrophil- or endothelial cell–derived adhesion molecules leads to significant cardioprotection in the setting of reperfusion injury.8–11 At present, there is no standard therapy for reperfusion injury that is widely accepted in the field. Moreover, myocardial ischemia in humans is often brought about by the long-term consequences of hypercholesterolemia (ie, endothelial dysfunction, plaque formation, fissures in arterial plaques, etc).12 Against this setting, cholesterol-lowering agents have been widely used to reduce cardiovascular risk.13–15 The major action of the HMG-CoA reductase inhibitors (eg, simvastatin, pravastatin, etc), collectively known as the “statins,” is inhibition of cholesterol synthesis in the liver.16 Recently, however, there has been a suggestion that these statins may exert effects separate from their cholesterol-lowering actions, including promotion of endothelial NO synthesis.17 We therefore tested the hypothesis that a clinically relevant dose of a widely used statin could exert an ameliorating effect on reperfusion injury in a neutrophil-dependent model of myocardial ischemia-reperfusion.
Methods

Isolated Rat Heart Preparation

Male Sprague-Dawley rats (270 to 320 g) were anesthetized with 60 mg/kg sodium pentobarbital, and sodium heparin 1000 U IP was administered (Elkins-Sinn). Hearts were rapidly excised, the ascending aorta was cannulated, and retrograde perfusion of the nonworking heart was initiated with a modified Krebs buffer maintained at 37°C and at a constant pressure of 80 mm Hg. The Krebs buffer had the following composition (in mmol/L): glucose 17, NaCl 120, NaHCO3 25, CaCl2 2.5, EDTA 0.5, KCl 5.9, and MgCl2 1.2. The perfusate was aerated with 95% O2/5% CO2, which was equilibrated at a pH of 7.3 to 7.4. Two side arms of the apparatus in the perfusion line just proximal to the heart inflow cannula allowed the infusion of PMNs and plasma directly into the coronary inflow line. To assess cardiac contractile function, a 2.5F microtip catheter transducer (Millar Instruments) was inserted directly into the left ventricular cavity, as previously described. The left ventricular pressures, dP/dtmax, and coronary flow were all recorded with a MacLab data acquisition system (AD Instruments) in conjunction with Power Macintosh 7600 computer (Apple Computers). All of these data were stored and analyzed at the end of each experiment. 

After the first 15 minutes of perfusion, baseline left ventricular developed pressure (+dP/dtmax), and coronary flow were all recorded with a MacLab data acquisition system (AD Instruments) in conjunction with a Power Macintosh 7600 computer (Apple Computers). All of these data were stored and analyzed at the end of each experiment. 

Quantification of CD18 Expression on Rat Isolated Neutrophils

Flow cytometric analysis of CD18 expression on the cell surface of freshly isolated rat neutrophils was performed according to standard procedures. Rat neutrophils were freshly isolated from rat whole blood according to the method of Williams et al. Isolated neutrophils were washed twice in calcium-free Tyrode’s solution containing 0.2% BSA and suspended in PBS. Neutrophils (5 × 10⁶ cells/tube) were incubated with anti-CD18 antibody (Wt. 3, Endogen) (4°C for 60 minutes). Excess primary antibody was then removed by washing of neutrophils in D-PBS. A goat anti-human IgG F(ab)2 FITC-conjugated antibody was used as the secondary antibody at a 1:100 dilution (4°C for 30 minutes). The stained neutrophils were washed twice with DPBS and finally fixed in 1% paraformaldehyde, and then analyzed by flow cytometry (FACScan, Becton-Dickinson).

Immunohistochemistry of P-Selectin Expression

Immunohistochemistry for P-selectin was performed on tissue sections embedded in plastic (ImmunoRed; Polysciences Inc) according to previously described techniques. The basic method used was the avidin-biotin immunoperoxidase technique with monoclonal antibody PB1.3 as the monoclonal antibody directed against P-selectin. Positive staining was defined as a coronary microvessel displaying brown reaction product on >50% of the circumference of its endothelium. Fifty vessels per tissue sample were examined in each of 3 hearts per group.

Neutrophil Adherence to Superior Mesenteric Artery Endothelium

Rat neutrophils were isolated as reported above. Segments of the superior mesenteric artery (SMA) were removed from control rats and simvastatin-treated rats, sectioned into 2- to 3-mm rings, opened, and placed into wells containing 2 mL Krebs-Henseleit (K-H) + 2% BSA solution. The SMA tissue was challenged with 2 U/mL thrombin (Sigma Immunochemicals) to induce P-selectin surface expression on the endothelium and coincubated with labeled PMNs (10⁷), as previously described. The number of adherent PMNs was counted by epifluorescence microscopy. Five different fields of each endothelial surface were counted, and the results are expressed as adherent PMNs/mm² of endothelium.

Effect of Simvastatin on NO Release From Isolated Rat Aortic Segments

We used freshly isolated rat aortic rings as the source of primary endothelial cells. Thoracic aortas isolated from control rats and simvastatin-treated rats were immersed in warm oxygenated K-H solution and cleaned of adherent fat and connective tissue. Aortic rings 6 to 7 mm long were carefully cut, opened, and fixed by small pins with the endothelial surface up in culture dishes containing 1 mL K-H solution. After equilibration at 37°C, NO released into the K-H solution was measured with a polarographic NO electrode (Iso-NO, World Precision Instruments, Inc) according to the method of Guo et al. Calibration of the NO electrode was performed daily before each experimental protocol. A standard calibration curve was obtained by graded concentrations of KNO2 at 0, 5, 10, 25, 50, 100, 250, and 500 nmol/L (final concentrations) into a calibration solution containing 0.1 mol/L KI and 0.1 mol/L H₂SO₄.

Statistical Analysis

All data in the text and figures are presented as mean ± SEM. The data on left ventricular function and coronary flow were analyzed by ANOVA incorporating repeated measures. Other data were compared by an ANOVA using post hoc analysis with Fisher’s corrected
Probability values of $0.05$ were considered to be statistically significant.

Results

To determine whether clinically relevant doses of simvastatin can attenuate leukocyte-endothelium interactions and improve cardiac contractile function in acute myocardial ischemia-reperfusion, we perfused nonischemic control rat hearts for 80 minutes at 80 mm Hg at a control flow of 20 to 25 mL/min or for 15 minutes at control flow followed by 20 minutes of total global ischemia and 45 minutes of reperfusion at control flows either with or without PMNs and plasma. Perfusion of additional simvastatin-treated hearts was also performed at a perfusion pressure of 80 mm Hg for 80 minutes. Perfusion of simvastatin-treated hearts at 80 mm Hg during sham ischemia or during ischemia-reperfusion without PMNs did not result in any change in coronary flow, LVDP, or $dP/dt_{max}$ at the end of the observation period, indicating that simvastatin did not exert any direct cardiodynamic effect. Furthermore, perfusion of untreated nonischemic hearts with PMNs did not alter any of the cardiac function variables measured, indicating that PMNs did not provoke cardiac dysfunction in normal nonischemic hearts. Only ischemic-reperfused rat hearts perfused with PMNs experienced a marked reduction in cardiac contractile function and coronary flow.

Ischemic-reperfused hearts perfused with PMNs and plasma exhibited significant cardiac dysfunction ($P<0.01$). Thus, coronary flow was decreased $27\pm3\%$ ($P<0.05$) from initial values (Figure 1), LVDP decreased $51\pm4\%$ from initial values ($P<0.01$) (Figure 2), and $dP/dt_{max}$ decreased $58\pm4\%$ from initial values ($P<0.01$) (Figure 3). This decrease in coronary flow and marked reduction in cardiac contractility can be attributed largely to the presence of PMNs at the time of reperfusion. This cardiac dysfunction is therefore due to the interaction of PMNs with the coronary microvascular endothelium. Against this background, simvastatin, given to rats 18 hours before isolation of the heart and subsequent induction of ischemia-reperfusion, markedly attenuated all 3 components of the cardiac dysfunction. Thus, simvastatin prevented the coronary flow deficit and enhanced LVDP and $dP/dt_{max}$ at the end of the reperfusion period whether hearts or only PMNs were used from simvastatin-treated rats (Figures 1, 2, and 3). Because no increase in coronary flow, LVDP, or $dP/dt_{max}$ occurred in nonischemic controls in the presence or absence of PMNs, these cardioprotective effects are not due to direct cardiodynamic effects of the simvastatin. Moreover, these salutary effects are unrelated to the cholesterol-lowering effect of simvastatin, because plasma cholesterol was $38\pm5$ mg/dL in 5 control rats, $44\pm3$ mg/dL in 5 simvastatin-treated rats, and $47\pm5$ mg/dL in 5 pravastatin-treated rats.

Five additional hearts treated with $25\mu g$ pravastatin and 5 with saline were subjected to the same ischemia-reperfusion...
protocol with PMNs as was the simvastatin group. The pravastatin-treated hearts responded significantly, although somewhat less than the simvastatin-treated hearts. Thus, final LVDP was 52±3 versus 88±3 mm Hg \((P<0.01)\) in saline-versus pravastatin-treated hearts, compared with 102±4 mm Hg initially. This corresponds to an 86\% recovery versus a 97\% recovery in simvastatin-treated hearts. Similarly, final \(+dP/dt_{max}\) was 2188±184 versus 3428±177 in saline- versus pravastatin-treated hearts \((P<0.02)\), compared with 4464±215 initially. This corresponds to a 77\% recovery compared with a 97\% recovery in simvastatin-treated hearts.

Because the cardiac dysfunction appeared to be due to the cardiodepressant actions of neutrophils on a sensitized ischemic-reperfused coronary microvasculature, we studied this interaction further. The first questions to be asked were: Do neutrophils infiltrate into the ischemic-reperfused rat heart? and Does simvastatin have any effect on this neutrophil infiltration? Histological counting of PMNs was used to assess PMN infiltration. Figure 4 summarizes the PMN infiltration data in these perfused rat hearts. None of the nonischemic control rat hearts or any of the ischemic-reperfused rat hearts perfused without PMNs exhibited any significant cardiac PMN infiltration. In contrast, ischemic-reperfused hearts perfused with PMNs exhibited an 8-fold increase in PMNs/mm\(^2\) of heart area \((P<0.01)\), indicative of significant PMN infiltration into these hearts. However, when either PMNs or hearts were isolated from simvastatin-treated rats and subjected to ischemia-reperfusion with PMNs, significantly lower numbers of infiltrated PMNs were observed.

To determine whether the endothelium of simvastatin-treated rats exhibited any changes in adhesion molecule expression that could account for the low degree of PMN involvement, we performed immunohistochemical analysis of P-selectin expression on the rat coronary microvascular endothelium. Figure 5 summarizes these results. Nonischemic controls exhibited very low P-selectin surface expression on the coronary endothelium. However, untreated rat hearts subjected to ischemia and reperfused with PMNs developed a 6-fold increase in P-selectin surface expression. This was markedly attenuated \((P<0.01)\) in ischemic-reperfused rat hearts whether or not the hearts or the PMNs were isolated from simvastatin-treated rats.

To determine whether simvastatin can moderate P-selectin-mediated PMN adherence to the endothelium, we studied PMN adherence to isolated vascular segments obtained from control or simvastatin-treated rats. Figure 6 summarizes these results. Thrombin was used to upregulate P-selectin expression on the endothelium. Vascular segments stimulated with thrombin 2 U/mL exhibited a 9-fold increase in PMN adherence \((P<0.001)\). This was totally blocked by a monoclonal antibody that neutralized P-selectin. Moreover, in experiments using either blood vessels or PMNs isolated
from simvastatin-treated rats, adherence was significantly attenuated. Thus, simvastatin exerts an antiadherence effect both on PMNs and on the endothelium. This antiadherence effect could be a major factor contributing to the cardioprotective effect observed in simvastatin-treated hearts.

Because the adherence studies suggested that at least part of the simvastatin effect was on neutrophils, we studied further the effect of simvastatin on PMN expression of the neutrophil surface adhesion molecule CD18 via flow cytometry. Figure 7 illustrates a representative flow cytometry histogram. Unstimulated PMNs taken from control untreated rats exhibited a normal distribution. Stimulation of control rat PMNs with 100 nmol/L leukotriene B4 (LTB₄) induced a marked shift to the right of the PMNs characteristic of activation. However, PMNs isolated from simvastatin-treated rats given LTB₄ remained largely unactivated, suggesting that simvastatin also exerts an antineutrophil effect that may be important in curtailing PMN-endothelium interaction.

To test whether the cardioprotective effects of simvastatin were due to increased bioavailability of NO, we measured NO release from aortic segments isolated from both vehicle- and simvastatin-treated rats. We detected a small basal level of NO release in aortic rings isolated from vehicle-injected rats (Figure 8). However, 18 hours after rats were given 25 mg simvastatin, the basal release of NO measured in aortic rings doubled (P<0.01). Moreover, the addition of an NO synthase (NOS)–inhibiting concentration of N-v-nitro-L-arginine methyl ester (ie, 100 μmol/L) inhibited NO release in aortic rings obtained from both vehicle-treated and simvastatin-treated rats (Figure 8). Therefore, systemic administration of simvastatin to the rats significantly increases endothelium-derived NO.

Discussion

It is well known that hypercholesterolemia, even in the absence of plaque formation, results in endothelial dysfunction. This endothelial dysfunction is characterized by a reduction in biologically active NO released from the endothelium. Whether this is due to an absolute reduction in endothelium-derived NO or in part to rapid quenching of NO by superoxide radicals remains to be clarified. In any event, moderate degrees of hypercholesterolemia do not physically injure the endothelium or induce its sloughing. Furthermore, increased plasma cholesterol levels in rabbits in the absence of atherosclerotic plaque formation has been shown to exacerbate reperfusion injury after myocardial ischemia.

One widely used means of controlling hypercholesterolemia is HMG-CoA reductase inhibitors, the statins. This is because they inhibit hepatic biosynthesis of cholesterol at the mevalonate step. This reduced cholesterol synthesis results in reduced coronary artery disease and stroke. Moreover, statins have been found to restore endothelial function toward normal in animals and humans. These effects are presumed to be due directly to reduced cholesterol synthesis,
leading to reduced cholesterol droplets in endothelial cells and therefore to preservation of endothelial function, including maintenance of NO release.

The present findings clearly point toward an action other than cholesterol lowering for the statins. In this study, either simvastatin or pravastatin given 18 hours before induction of myocardial ischemia exerted a marked cardioprotective effect of dramatically blunting reperfusion injury. The data also suggest that statins attenuated neutrophil-endothelium interaction in the coronary microvasculature. Several possibilities may explain the cardioprotective effects of statins at normal cholesterol levels. These mechanisms all relate to preservation of endothelial function, inhibition of neutrophil activation, or a combination of the two effects.

With regard to neutrophil function, it is known that lovastatin reduces monocyte CD11b expression and monocyte adhesion to the endothelium in patients independently of its cholesterol-lowering effect. CD11b is the α-chain of the β2-integrins, which participates in an important way in promoting firm adhesion of leukocytes to the endothelium. In our studies, we assessed the common β2-chain of the β2-integrins, CD18, in rat neutrophils. Simvastatin clearly attenuated LTB4 upregulation of CD18. Moreover, statins significantly inhibited neutrophil and monocyte chemotaxis in human blood cells. This effect could partially explain the results obtained in the present study. Thus, there is evidence that the statins may exert anti-inflammatory actions on blood cells in the absence of hypercholesterolemia.

A second and perhaps related effect of the statins may be upregulation of endothelial NO synthesis as well as inhibition of hypoxia-mediated inhibition of NOS activity. Maintenance of endothelium-derived NO may be a very important aspect of the cardioprotective effects of simvastatin. NO exerts a variety of important homeostatic actions that could help explain these results. NO has been shown to act as a physiological inhibitor of leukocyte–endothelial cell interaction by suppressing upregulation of several endothelial cell adhesion molecules, including P-selectin, VCAM-1, and ICAM-1. NO is able to inhibit neutrophil-induced cardiac dysfunction by preserving endothelial release of NO. Similar salutary effects were observed with simvastatin and lovastatin in mice subjected to cerebral ischemia-reperfusion. These effects were dependent on enhanced NO formation, because they did not occur in endothelial constitutive NOS knockout mice, and were unrelated to the inhibitory effect of simvastatin on cholesterol biosynthesis. Moreover, this endothelial preservation with its subsequent attenuation of neutrophil activation effectively prevents neutrophil-induced cardiac dysfunction. In this regard, we have presented new evidence showing that simvastatin significantly increases basal NO release from the vascular endothelium by a specific mechanism involving NOS. This increased bioavailability of NO is likely to attenuate P-selectin upregulation on the coronary microvascular endothelium, thus limiting neutrophil adherence to the endothelium during inflammatory conditions. These effects may relate to purported effects of the statins on remodeling of the vessel wall, which may be partially due to enhanced NO generation. Thus, the statins may have important biological effects that promote endothelial preservation and vascular homeostasis independently of their cholesterol-lowering effects. These actions may have important applications in attenuating leukocyte-induced cell injury such as that occurring in reperfusion injury.

Acknowledgment
This study was supported in part by research grant GM-45434 from the National Institutes of Health.

References


Simvastatin Preserves the Ischemic-Reperfused Myocardium in Normocholesterolemic Rat Hearts
Allan M. Lefer, Barry Campbell, Yong-Kyoo Shin, Rosario Scalia, Reid Hayward and David J. Lefer

Circulation. 1999;100:178-184
doi: 10.1161/01.CIR.100.2.178

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/100/2/178

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/